resources were derived from public sources. One and two-way sensitivity analyses were performed for key input variables. Budget impact analysis extrapolates results of the (CM), using prevalence data, to a health plan with 1 million covered lives. An alternate time-dependent model addresses the impact associated with the sequencing of diagnostic tests. Results: The CM model predicts a base-case savings of $280 per patient for the diagnostic pathway that includes the novel IBS diagnostic blood panel. Sensitivity analyses predict a range of cost savings of $120 -$439. Budget impact analysis predicts a base case savings of $1,080,232 to the plan or $0.09 on a per member per month basis for the diagnostic pathway with the novel IBS diagnostic blood panel. The time dependent model indicates that the potential cost savings associated with the novel IBS blood test are attenuated over time. ConClusions: Current literature suggests that extensive diagnostic testing to diagnose IBS is not necessary. This economic evaluation indicates that the inclusion of a novel IBS diagnostic blood panel in the diagnostic process has the potential for significant cost savings due to the avoidance of unnecessary testing.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.